Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIB/IV Randomized, Controlled, Open-label, Parallel Group Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration Fidaxomicin Therapy in the Sustained Clinical Cure of Clostridium Difficile Infection in an Older Population

NCT02254967 is registered in ClinicalTrials.gov with Astellas Pharma Europe Ltd. as lead sponsor.

NCT NCT02254967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02254967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIB/IV Randomized, Controlled, Open-label, Parallel Group Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration Fidaxomicin Therapy in the Sustained Clinical Cure of Clostridium Difficile Infection in an Older Population
Lead sponsor
Astellas Pharma Europe Ltd.
Phase
Phase 4
Overall status
Completed
Start date
November 6, 2014
Completion date
May 5, 2016
Enrollment
364 (actual)
Sites
109

Conditions

As the registry lists them; a condition with its own page is linked.

clostridium difficile